18. Biofuels II -> biofuels and biochemicals
Production of acetone using Clostridium
Produced in Clostridium acetobutylicum
Ferments sugars to acetone, butanol and ethanol (ABE process)
Natural process under anaerobic conditions
Ethanol, acetone and butanol secreted from the cell (reduces costs)
This process could not compete with production from petroleum after WW2
Over 6,000 items are currently produced from oil
We are going to have to find renewable, low cost, alternatives within the next hundred years (preferably sooner)
What are the major issues in using microbes to produce chemicals
A. Cost
B. Genetically engineering a strain that stably produces high amounts of the chemical
C. Mutation of genetically engineering strains
D. Scaling up processes to industrial scale
E. All of the above
Microbial production of organic and amino acids
For some compounds, microbial production has always been the optimal route (organic acids, amino acids, vitamins)
Production occurs at huge scale
Well established processes
MSG sells for about £5-10 a kg on amazon (low to medium value product)
All amino acids are industrially produced via natural cellular processes
Genetically engineering organisms for production of novel compounds
Only a few products are naturally produced by microbes in quantities sufficient for commercialisation
For synthesis of novel compounds or to increase production (and secretion) of novel compounds organisms have to be genetically engineered
Characterisation of the appropriate biosynthetic pathway is required for production of novel compounds
What properties are important when choosing a species for production of chemicals
A. Fast growth
B. Amenability to genetic manipulation
C. Production of precursors for the desired chemical
D. Ability to export chemicals from the cell
E. All of the above
Production of diesel in Escherichia coli
Expressed the pathway in E. coli
Claimed that hydrocarbons were secreted into the media
Were adding a small amount of detergent that was lysing cells
Built a pilot plant
Process wasn’t commercial
Company sold in 2013
Introduced a pathway for production of branched fatty acyl-ACPs
Introduced the cyanobacterial hydrocarbon biosynthesis pathway Hydrocarbons were not secreted into the media
Producing hydrocarbons similar to petrol in Escherichia coli
Modified an enzyme that produces smaller fatty acids
Alkanes ranged from C8 to C16
Smaller alkanes were secreted from the cell
The final engineered strain produced up to 580.8 mg l(-1) of SCAs consisting of nonane (327.8 mg l(-1)), dodecane (136.5 mg l(-1)), tridecane (64.8 mg l(-1)), 2-methyl-dodecane (42.8 mg l(-1)) and tetradecane (8.9 mg l(-1))
Producing artemisinin in yeast - the great synthetic biology success story
Artemisinin is an anti-malarial drug derived from the plant Artemisia annua
Plant derived artemisinin fluctuated in price and production varied hugely from year to year
Used synthetic biology to express the artemisinic acid pathway in Saccharomyces cerevisiae
Up-regulated production of the precursor-farnesyl pyrophosphate (FPP)
Introduced Four novel genes for production of artemisinic acid
Artemisinic acid secreted from the cell
Yields are now at 25 g per litre (small-scale batch process)
Production costs are between $US350-400 per kg
Can’t compete with plant derived artemisinin (the price stabilised after this process was developed)
Production plant was sold by Sanofi
Adapting this process for production of farnesene
Farnesene is a low value hydrocarbon which can be used as a biofuel or chemical feedstock
Single enzyme required for production of farnesene from farnesyl pyrophosphate
Enzymes introduced into yeast to increase production of farnesyl pyrophosphate (FPP)
Farnesene synthase introduced into yeast for production of farnesene
Farnesene is a low value chemical
Farnesene is a low value (~US$3 a kg) hydrocarbon which can be used as a biofuel or chemical feedstock
To be commercial, production has to occur at large scale and be robust
Built an expensive plant (40 million liter capacity)
Brazilian sugar cane was used as the feedstock
Similar process as used for producing ethanol in yeast except the process does not rely on fermentation
One billion dollars later
Predicted production of 9 million litres in 2011, 44-50 million litres in 2012
This was reduced to 1-2 million litres in 2011. Even this target wasn’t met
The plant was sold for US$96 million in 2017 (with IP)
Now focusing on ‘high value’ chemicals
Investors are still not impressed → Investors have lost over 1 US billion dollars
What are the major issues with genetically engineering an organism to produce large amounts of chemicals
A. Time taken to engineer the organism
B. Diverts energy away from growth
C. May toxify the media
D. May not be scalable
What went wrong?
The company has not divulged what went wrong (despite receiving public money)
Two likely possibilities
Upscaling
Mutation of strains
Upscaling problems include mixing, aeration, cleaning, contamination, reusing yeast
Evolution will always win
A scientific man ought to have no wishes, no affections, - a mere heart of stone Charles Darwin
Diverting energy and resources from growth towards production of a specific compound is not to the organism’s advantage
Therefore your engineered strain is less fit
Any mutant that rediverts energy and resources from production of a specific compound back towards growth will have a selective advantage
Which genetic mutation is likely to be more stable?
A. Deletion of a native gene
B. Over-expression of a foreign or native gene
Inactivating genes is relatively easy for microbes
Deletion of genes is a relatively stable mutation (Harder to find a substitute gene to compensate for its loss)
Relatively easy to inactivate a gene (mutation in an essential amino acid)
A similar situation happened with cyanobacterial biotechnology
Company went bankrupt in 2017. Investors lost over 200 US million dollars
Re-calibrating the field
Failures re-focused the field
Focus on higher value products
Improving production methods
Better strains
Unique products
High vs low value compounds
All ‘viable’ companies are focusing on ‘high value’ compounds
Nutraceuticals
Pharmaceuticals
Specialty chemicals
Higher value compounds can be produced using lower volume batch cultures
Solves two issues
Upscaling → from lab scale to bioreactors with 10s to 100s of litres is not as challenging
Genetic mutation is not as great an issue
Can start with fresh starter cultures
Cheaper to clean out bioreactors
Shorter culture periods
Less cells
Success is dependent on value of products
Artemisinin was ~US$350-400 a kg
Making unique specialist products is the best option
Spider silk is tougher than steel or Kevlar BUT you can’t farm spiders
Using E. coli to make spider silk
Spinning artificial spider silk
Maybe focus on really, really high value products
Sea silk (byssus)- the most valuable fabric in human history
Genesis 41:42
And Pharaoh took off his ring from his hand, and put it on Joseph's hand, and arrayed him in clothes of byssus, and put a gold chain on his neck.
Reportedly, a Japanese businessman offered US$3 million for a square of fibre of 18 inches per side